solo 2
play

SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer - PowerPoint PPT Presentation

Closed Trial status update SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer Trial setting: Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer Study Design: A


  1. Closed Trial – status update SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer Trial setting: Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer Study Design: A Phase III, Randomised, Double Blind, Placebo Controlled Sponsor(s): AstraZeneca Final No. of patients: 295 Timeline (first patient – trial closing): Aug 2013- Aug 2021 Publications: In submission Planned publications and substudies: To be discused at the SOLO-2 TSC meeting (June 3rd 6:30 am) SOLO-2 - GCIG June 1st 2017

  2. Primary Endpoint presented at SGO on March 2017 SOLO-2 - GCIG June 1st 2017

  3. Tomorrow , do not miss …. • M. Friedlander Oral presentation on QOL data • Poster discussion on Tolerability SOLO-2 - GCIG June 1st 2017

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend